Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Journal of Neurodevelopmental Disorders

Fig. 1

From: Recent progress and considerations for AAV gene therapies targeting the central nervous system

Fig. 1

Packaging capacity of AAV. a Plot of CDS size in bases versus percentile as determined via analysis of all human CDSs in GENCODE 28. b Top panel: cartoons of single-stranded (ss) and self-complementary (sc) AAV with indicated packaging capacities. Bottom panel: calculations of gene of interest size as well as percent of transcriptome covered and number of CDSs not covered at the indicated capacities. The gene/promoter combinations for a relatively strong promoter (CBh) [118] and relatively weak promoter (JeT) [119, 120] are provided as examples to demonstrate relevant gene packaging possibilities

Back to article page